Current Endocrine Therapy in Hormone-Receptor-Positive Breast Cancer: From Tumor Biology to the Rationale for Therapeutic Tunning

Current Endocrine Therapy in Hormone-Receptor-Positive Breast Cancer: From Tumor Biology to the Rationale for Therapeutic Tunning

<i>Background and Objectives</i>: The objective of this review is to evaluate the current evidence regarding hormone treatments for both premenopausal and postmenopausal women with early-stage hormone receptor (HR) positive breast cancer. <i>Materials and Methods:</i> An in-d...

Full description

Saved in:

Bibliographic Details
Main Authors:	Oana Maria Burciu, Adrian-Grigore Merce, Simona Cerbu, Aida Iancu, Tudor-Alexandru Popoiu, Ionut Marcel Cobec, Ioan Sas, Gabriel Mihail Dimofte
Format:	Article
Language:	English
Published:	MDPI AG 2025-07-01
Series:	Medicina
Subjects:	breast cancer hormone therapy tamoxifen aromatase inhibitors
Online Access:	https://www.mdpi.com/1648-9144/61/7/1280
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Adjuvant endocrine treatment strategies for non-metastatic breast cancer: a network meta-analysisResearch in context
by: Andri Papakonstantinou, et al.
Published: (2025-03-01)

Cardiovascular risks associated with adjuvant endocrine therapy in women with breast cancer: a population-based cohort study
by: Iokfai Cheang, et al.
Published: (2025-07-01)

Adjuvant hormone therapy in postmenopausal patients with locally advanced breast cancer: hope and reality
by: V. I. Borisov
Published: (2014-07-01)

Comparative study of the efficacy of tamoxifen and aromatase inhibitors among breast cancer patients at Kenyatta National Hospital
by: Henry Gachoki Macharia, et al.
Published: (2025-08-01)

Younger tamoxifen-treated breast cancer patients also had higher risk of endometrial cancer and the risk could be reduced by sequenced aromatase inhibitor use: A population-based study in Taiwan
by: Sung-Chao Chu, et al.
Published: (2020-01-01)

Update in the clinical utilization of chemoprevention for breast cancer: a narrative review
by: Razan Mansour, et al.
Published: (2025-06-01)

Cardiovascular and metabolic effects of ovarian suppression in combination with tamoxifen or an aromatase inhibitor as adjuvant therapy for early oestrogen receptor-positive breast cancer: a systematic review
by: Ying X. Gue, et al.
Published: (2024-07-01)

Aromatase inhibitors therapy and major osteoporotic fracture risk in postmenopausal breast cancer patients: a nationwide real-world cohort study
by: Pin-Han Liu, et al.
Published: (2025-05-01)

Escalation and De-Escalation Strategies for Endocrine Therapy in Early-Stage Breast Cancer
by: Al-Batsh T, et al.
Published: (2025-03-01)

Lesson from a metastatic male breast cancer case: CDK4/6 plus aromatase inhibitors could not exceed tamoxifen
by: Tala Najdi, et al.
Published: (2025-05-01)

Real-world utilization of aromatase inhibitors, tamoxifen, and ovarian function suppression in premenopausal patients with early hormone receptor-positive, HER2-negative breast cancer with increased recurrence risk
by: Volkmar Müller, et al.
Published: (2025-06-01)

Peripheral precocious puberty in girls with McCune-Albright syndrome: a case series
by: Aline Guimarães Faria, et al.
Published: (2025-05-01)

Systematic literature review and trial-level meta-analysis of aromatase inhibitors vs tamoxifen in patients with HR+/HER2− early breast cancer
by: Wolfgang Janni, et al.
Published: (2025-06-01)

Medications to reduce breast cancer risk: a network meta-analysis of randomized controlled trials
by: Ghazaleh Pourali, et al.
Published: (2025-07-01)

Impact of Endocrine Therapy on Osteoporosis Risk in Women with Breast Cancer Across Different Hormonal Stages: A Review
by: Beatriz Gomes, et al.
Published: (2025-05-01)

Short-duration preoperative endocrine therapy alters molecular profiles to predict favourable outcome in ER+/HER2+ early breast cancer: a POETIC translational studyResearch in context
by: Milana Bergamino Sirvén, et al.
Published: (2025-08-01)

The effects of adjuvant endocrine therapy on long-term outcomes from ductal carcinoma in situ: a systematic review and meta-analysis
by: Qian Chen, et al.
Published: (2025-08-01)

Tamoxifen-Induced Cutaneous Vasculitis—A Rare Case Report with Review of Literature
by: Ankita Das, et al.
Published: (2024-04-01)

Electrochemical biosensor for simultaneously detection of Tamoxifen
by: Hasret Subak
Published: (2022-12-01)

Trends in Combinatorial Endocrine Therapy for Breast Cancer Across Six Cities in China(2016-2021)
by: Wang C, et al.
Published: (2025-05-01)

Benefits of aromatase blockers for increased testosterone in poultry: A mini-review
by: Rizki Fitrawan Yuneldi, et al.
Published: (2025-05-01)

Postmarketing assessment of a switchable similar anastrozole product in Brazilian breast cancer patients
by: Manuela Vasquez Cardoso, et al.
Published: (2023-04-01)

Discovery to Engineering of Mycotoxin Deoxynivalenol Degrading Enzymes Based on the Specialized Glyoxalase I
by: Seung Hee Lee, et al.
Published: (2025-08-01)

Estrogen receptor alpha dynamics and plasticity during endocrine resistance
by: Aswathy Sivasailam, et al.
Published: (2025-06-01)

Ovarian function suppression: To what extent is it necessary for premenopausal patients with operable hormone-sensitive breast cancer?
by: P. V. Koposov
Published: (2015-09-01)

Treatment Modalities for Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS): A Scoping Review of Prospective Treatment Studies
by: Bobo JA, et al.
Published: (2025-04-01)

Targeting EPAS-1/HIF-2α Pathway to Address Endocrine Resistance in Luminal A Type Breast Cancer
by: Enzhi Luo, et al.
Published: (2025-07-01)

Aromatase Gene Expression in N-Ethyl-Nitrosamine-Induced Hepatocellular Carcinoma: Hepatoprotective Effects of Grape Seed Extract and Letrozole
by: Sadia Kazi, et al.
Published: (2024-11-01)

Lactobacillus gasseri CCFM1255 promotes peripheral estrogen synthesis in ovariectomized rats by modulating the gut microbiome and serum metabolome
by: Qian Chen, et al.
Published: (2024-11-01)

Association between the aromatase (CYP19A1) gene variant rs10046 and cardiovascular risk in postmenopausal women
by: Betânia Rodrigues dos Santos, et al.
Published: (2025-01-01)

Nebivolol effect on oxidative biomarkers in Tamoxifen-Induced Hepatotoxicity in Female White Albino Rats: In Vivo Study
by: Noor Ahmed Hammadi, et al.
Published: (2025-05-01)

Two natural products from the seeds of Citrus reticulata Blanco (Rutaceae) inhibit estrogen biosynthesis by regulating the PI3K-aromatase pathway
by: Xing Yang, et al.
Published: (2025-06-01)

Molecular characterisation of the residual disease after neoadjuvant endocrine therapy in ER+/HER2- breast cancer uncovers biomarkers of tumour response
by: Joanna I. López-Velazco, et al.
Published: (2025-07-01)

D-chiro-inositol effectively counteracts endometriosis in a mouse model
by: Martina Placidi, et al.
Published: (2025-04-01)

Toxic effects of monocrotophos and glyphosate on the female reproductive organ and aromatase gene expression in climbing perch
by: Sujata Mohapatra, et al.
Published: (2025-01-01)

Analysis of advanced non-small cell lung cancer course during high dose antiestrogen therapy use in complex chemoradiotherapy treatment of patients
by: A. V. Kadzhoian
Published: (2014-12-01)

Estrogen Receptor Expression in Tumors Different from Breast Cancer
by: T. A. Bogush, et al.
Published: (2020-05-01)

Prediction of menstrual recovery patterns in premenopausal women with breast cancer taking tamoxifen after chemotherapy: an ASTRRA Substudy
by: Young Joo Lee, et al.
Published: (2024-11-01)

Extracellular vesicles from human breast cancer-resistant cells promote acquired drug resistance and pro-inflammatory macrophage response
by: Patrick Santos, et al.
Published: (2024-10-01)

Evaluation of the androgen receptor in patients with ERα-positive early breast cancer treated with adjuvant tamoxifen ± fluoxymesterone
by: James N. Ingle, et al.
Published: (2025-03-01)